企業プロフィール
Syndax Pharmaceuticals 株価・ニュース・カタリスト
- ティッカー:
- SNDX
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
19.76 USD (-0.40%)
終値
最終更新: 2026年8月17日
1.63B USD
時価総額
株価変動の要因
As of Aug 17, 2026, SNDX closed down 0.40% at $19.76. No new same-company headline was identified in the current news window.
企業概要
Commercial Oncology Portfolio
Syndax Pharmaceuticals develops and commercializes therapies for genetically defined leukemias and immune-mediated complications of transplantation. Its commercial portfolio is built around Revuforj and Niktimvo.
Revuforj
Revuforj, or revumenib, is a menin inhibitor used in acute leukemias with susceptible genetic drivers. Ongoing studies evaluate frontline combinations, post-transplant maintenance and additional molecular subgroups, including NPM1-mutant, KMT2A-rearranged and NUP98-rearranged disease.
Niktimvo
Niktimvo, or axatilimab, targets CSF-1 receptor biology and is commercialized for chronic graft-versus-host disease. Syndax is testing the molecule in newly diagnosed chronic GVHD and idiopathic pulmonary fibrosis to expand beyond its initial indication.
Frontline Registrational Strategy
Syndax is advancing pivotal trials intended to establish revumenib in frontline acute myeloid leukemia. It also plans the RAVEN study as part of the asset’s broader development program.
今後のカタリスト
- New revumenib real-world, frontline and post-transplant maintenance data expected in the second quarter of 2026.
- Additional revumenib data presentations from ongoing studies during the second half of 2026.
- Initiation of the RAVEN trial expected in the second half of 2026.
- Topline Phase 2 data for axatilimab in idiopathic pulmonary fibrosis and newly diagnosed chronic GVHD expected in the fourth quarter of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。